Skip to main
REPL

REPL Stock Forecast & Price Target

REPL Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 13%
Buy 13%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

Replimune Group is a promising company in the biotechnology sector with a diverse pipeline of novel oncolytic immunotherapies targeting solid tumors. The company's leading product candidate, RP1, has shown potential in treating advanced melanoma, a difficult-to-treat cancer. With a strong focus on leveraging its RPx platform to activate the immune system against cancer, Replimune Group has the potential for significant growth and success in the future.

Bears say

Replimune Group is facing a negative outlook due to the disappointing results from their RP1 treatment, with an overall response rate significantly lower than other treatments in the same patient population. In addition, the FDA has raised concerns about the trial design of their ongoing Phase 3 study and the company's limited cash resources may hinder their ability to continue development. The potential need for restructuring and decreased probability of success for RP1 ultimately led to the downgrade to a Neutral rating and a decrease in the price target to $2.

REPL has been analyzed by 8 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 13% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Replimune Group Inc (REPL) Forecast

Analysts have given REPL a Hold based on their latest research and market trends.

According to 8 analysts, REPL has a Hold consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Replimune Group Inc (REPL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.